IGHE and Alzheimer disease: They bind mIgE+ B cells (Figure 5A) and neutralize soluble IgE in buffer solution (Supplemental Figure 7) and high IgE in sera of patients with AD (Figure 7) equally strongly, despite differing in IgE binding by SPR (Figure 6), which shows a 4-fold lower affinity for UB-221 observed under a covalent sensor-chip-coupling setting different from that reported earlier for ligelizumab (35).